GlaxoSmithKline yesterday signed two new deals to boost its pipeline of products in development while receiving a setback on another drug that was close to launch.

The company agreed to pay undisclosed upfront cash payments and an equity stake in OncoMed Pharmaceuticals, a privately held US company, to be followed by milestones totalling up to $1.4bn (£684m).